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Objectives. We assessed the acute effect of intracoronary injec-
tion of verapamil on microvascular function after primary percu-
taneous translumanal coronary angioplasty (PTCA) for acute
myocardial infarction (AMI) with myocardial contrast echocardi-
ography (MCE) in relation to functional outcomes.
Background. Recent clinical studies have documented the po-
tential of verapamil for possible increase in coronary blood flow
after primary PTCA.
Methods. Forty patients with a first AMI were randomly
assigned to the verapamil group (n 5 20) or the control group
(n 5 20). In the verapamil group, verapamil (0.5 mg) was injected
into the infarct-related artery shortly after PTCA, followed by the
oral administration. We performed MCE with an intracoronary
injection of sonicated microbubbles before and after verapamil.
To assess microvascular integrity, we determined the baseline-
subtracted peak intensity in the risk area and the ratio of the no
reflow zone plus the low reflow zone to the risk area (low reflow
ratio). We determined the average wall motion score (dyskinesia/
akinesia 5 3; normal 5 0) in the risk area on the day of AMI and
a mean of 24 days later.
Results. The low reflow zone was observed shortly after PTCA
in 14 verapamil group patients, and the low reflow ratio decreased
after verapamil (0.39 6 0.23 vs. 0.29 6 0.17 [mean 6 SD], p <
0.05). Peak intensity significantly (p < 0.05) increased from 6 6
5 to 12 6 6 after verapamil. The reduction in wall motion score
from the acute (day 21) to the late stage (day 224) was
significantly greater in the verapamil group than in the control
group (0.7 6 0.8 vs. 0.2 6 1.3, respectively, p < 0.05).
Conclusions. Intracoronary administration of verapamil after
primary PTCA can attenuate microvascular dysfunction and
thereby augment myocardial blood flow in patients with AMI,
leading to better functional outcome than with PTCA alone.
(J Am Coll Cardiol 1997;30:1193–9)
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Coronary reperfusion has been established as an essential
therapy for acute myocardial infarction (AMI). Originally, its
benefit was considered to be due to timely reestablishment of
blood flow to the previously ischemic myocardium. However,
we and other investigators have documented (1–6) that myo-
cardial blood flow is occasionally profoundly reduced, even
after coronary recanalization, because of microvascular dys-
function in patients with an AMI. This no reflow phenomenon
is associated with profound and broad myocardial damage,
progressive left ventricular dilation and a high frequency of
post-AMI complications (4,7).
Several studies have attempted to attenuate ischemic mi-
crovascular dysfunction with pharmacologic intervention. In a
canine study, Stahl et al. (8) demonstrated that postischemic
myocardial function can be selectively enhanced by augmen-
tation of blood flow with the intravenous administration of
papaverine. In another canine study, Babitt et al. (9) demon-
strated that intracoronary administration of adenosine atten-
uates the progression of microvascular dysfunction after reper-
fusion. This was associated with an improvement in
postischemic myocardial function. In a clinical study, Piana et
al. (10) reported that intracoronary verapamil can augment
postinterventional coronary blood flow, possibly due to the
reversal of microvascular spasm. However, no direct evidence
exists as to verapamil’s ability to improve postischemic micro-
vascular function in patients with an AMI or whether such an
improvement would lead to a better functional outcome than
with coronary reperfusion alone.
In the present study, we performed myocardial contrast
echocardiography (MCE) before and after intracoronary in-
jection of verapamil to clarify the direct effect of verapamil on
postischemic microvascular function in patients with a reper-
fused AMI. We then compared functional outcomes in pa-
tients with and without verapamil treatment to study the
relation between microvascular protection and myocardial
salvage.
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Methods
Patients. The study included 43 patients who met the
following criteria: 1) admission to our hospital with a diagnosis
of a first AMI; 2) single-vessel disease; 3) percutaneous
transluminal coronary angioplasty (PTCA) of a totally oc-
cluded infarct-related artery (Thrombolysis in Myocardial In-
farction [TIMI] flow grade 0) within #12 h of symptom onset;
4) residual diameter stenosis ,50%; 5) no ischemic event
during follow-up; and 6) adequate quality of echocardiogram.
The diagnosis of AMI was made on the basis of chest pain
$30 min, AMI-compatible ST segment elevation $2 mm on
electrocardiographic leads and threefold or greater increase in
serum creatine kinase levels. After primary PTCA, we ran-
domly assigned the patients to the verapamil or control group.
Three patients were excluded from the study because of severe
congestive heart failure at baseline, leaving a final cohort of 40
patients, 20 of whom were assigned to the intracoronary
verapamil group and 20 to the control group. Clinical charac-
teristics of the two groups are shown in Table 1. There was no
difference in baseline characteristics or prehospital and in-
hospital medication between the two groups. The hospital
ethics committee approved the study protocol, and written
informed consent was obtained from each patient by one of the
investigators (Y.T., H.I., K.J., S.T., N.N.).
Protocol. Patients underwent catheterization by the femo-
ral approach on the day of the AMI. On completion of
diagnostic coronary angiography and left ventriculography, 2
ml of sonicated Ioxaglate (Hexabrix-360, Tanabe) containing
sonicated microbubbles (mean size 12 mm) was injected into
the left main coronary artery for MCE (4,5). We initiated
imaging of the apical long-axis and parasternal short-axis views
;10 s before the contrast injection and continued for an
average of 30 s with a constant gain setting with a commercially
available mechanical sector scanner (model SAL-38B,
Toshiba, carrier frequency of 3.5 MHz). We recorded these
images on 1.25-cm videotape using a VHS recorder (model
BR-6000, Victor). After another contrast injection into the
right coronary artery, MCE was repeated. Each patient then
underwent primary PTCA. At a mean of 16 min after PTCA,
we performed coronary angiography using a 6F diagnostic
catheter and recorded the right anterior oblique projection for
evaluation of coronary blood flow. We also performed MCE
using the same procedure as before, after which 0.5 mg of
verapamil, diluted to a total volume of 10 ml with saline, was
injected into the infarct-related artery over 1 minute in the
verapamil group patients. We then repeated coronary angiog-
raphy and MCE. In the verapamil group, 120 mg of verapamil
was orally administered until the follow-up study.
We performed multiplane two-dimensional echocardiogra-
phy before PTCA and at a mean of 24 days after the AMI using
a commercially available sector scanner (model SSH-65A,
SSH-260A, Toshiba, carrier frequency of 3.75 MHz or
2.5 MHz). We recorded echocardiographic images on 1.25-cm
VHS videotape. We repeated coronary angiography and left
ventriculography at a mean of 25 days after the AMI (24 to 29
days) using the right brachial approach.
Analysis of echocardiographic data. An experienced echo-
cardiographer (Y.T., H.I.) analyzed MCE images with an
off-line image analyzing system (Color Cardiology Worksta-
tion, TomTec). MCE images were analyzed to identify risk
areas and areas of “no reflow,” as described elsewhere (4,5). In
brief, we defined the areas at risk and no reflow in end-diastolic
images as contrast perfusion defects before and after PTCA,
respectively. We quantified the area of no reflow as the ratio to
the risk area (no reflow ratio). When the ratio exceeded 25%,
myocardial reperfusion in the corresponding segment was
considered incomplete (MCE no reflow). If this ratio was
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ANOVA 5 analysis of variance
LV 5 left ventricular
MCE 5 myocardial contrast echocardiography
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
Table 1. Clinical Characteristics of Study Patients
Verapamil
Group
(n 5 20)
Control
Group
(n 5 20)
p
Value
Age (yr) 61 6 11 67 6 14 0.28
Men 75% 80% 0.66
Symptom onset–reflow time
(h)
7.1 6 3.1 7.6 6 3.8 0.61
HR (beats/min)* 72 6 13 70 6 15 0.62
SBP (mm Hg)* 144 6 15 142 6 16 0.57
DBP (mm Hg)* 80 6 10 76 6 14 0.24
Non-Q wave MI 10% 5% 0.56
Collateral grade $II† 20% 25% 0.71
IRA (LAD) 65% 70% 0.74
TIMI flow grade 3 after PTCA 70% 75% 0.73
Low reflow ratio 0.28 6 0.26 0.26 6 0.24 0.80
Risk factors
Smoking 65% 60% 0.75
Diabetes mellitus 15% 20% 0.68
Hypertension 45% 35% 0.53
Hyperlipidemia 25% 30% 0.73
Premedication
Ca antagonist 35% 25% 0.50
Beta-blocker 10% 5% 0.56
ACE inhibitor 25% 15% 0.42
In-hospital medication
Nitrates 95% 100% 0.32
Beta-blocker 10% 20% 0.39
ACE inhibitors 55% 60% 0.75
Diuretic drug 15% 25% 0.44
Aspirin 100% 100% NS
*Values measured on admission. †Cohen classification. Data presented are
mean value 6 SD or percent of patients. ACE 5 angiotensin-converting enzyme;
Ca 5 calcium; DPB 5 diastolic blood pressure; HR 5 heart rate; IRA 5
infarct-related artery; LAD 5 left anterior descending coronary artery; MI 5
myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty;
SBP 5 systolic blood pressure; TIMI 5 Thrombolysis in Myocardial Infarction.
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#25%, we considered myocardial reperfusion to be adequate
(MCE reflow). We previously demonstrated (4) the high
reproducibility of measuring the size of contrast defect. There
were myocardial segments that were opacified in a patchy
fashion or only in the epicardial layer around the no reflow
zone. Ragosta et al. (11) defined such segments as “low reflow”
and documented relatively poor functional improvement of
these segments. In the present study, we also calculated the
ratio of the no reflow area plus the low reflow area to the risk
area (low reflow ratio).
Microvascular integrity was assessed with baseline-
subtracted contrast intensity in the risk area because contrast
intensity is considered to be proportional to myocardial blood
volume, which, in turn, is closely related to the density of intact
microvascular volume. We previously described (5) our
method for determining postintervention contrast intensity in
the risk area. Briefly, we identified the initial risk area in the
postreflow MCE images by referencing pre-PTCA MCE im-
ages. Excluding the endocardial and epicardial borders, we
measured contrast peak intensity of the entire myocardial
segment of the risk area before and after contrast injection to
determine the baseline-subtracted peak intensity (unit/pixel,
256 gray scale; 0 5 black; 255 5 white).
Left ventricular wall motion was evaluated at baseline and
at follow-up, as previously reported (4). We scored 17 seg-
ments of the left ventricle using the following system: 3 5
dyskinetic/akinetic; 2 5 severely hypokinetic; 1 5 hypokinetic;
0 5 normal. The wall motion score index was defined as the
mean score of the segments showing asynergy at baseline. Two
independent observers (K.I., S.T.) who had no knowledge of
the clinical data determined the segmental score, and a third
observer established consensus in cases of disagreement.
Analysis of catheterization data. After mechanical causes
of flow reduction, such as critical residual coronary stenosis,
apparent dissection, thrombosis or distal vessel cutoff sugges-
tive of macroembolization, were excluded, two radiologists
with no knowledge of patient data determined the Thrombol-
ysis in Myocardial Infarction (TIMI) flow grade of the infarct-
related artery before and after verapamil (6). TIMI flow grades
have been defined elsewhere (12). In three cases of disagree-
ment, the final TIMI grade was determined by the consensus of
the two radiologists (N.N., Y.H.). Using a cine projector
equipped with a frame counter, an angiographer (N.N.) re-
corded the number of cineframes required from initiation of
contrast injection to the opacification of a specified distal
landmark (frames to opacification) (10,13). These measure-
ments were performed before and after administration of
verapamil. An angiographer (N.N.) who had no knowledge of
patient data quantified the percent coronary diameter stenosis
of the infarct-related artery by the use of a validated technique
and analyzed the right anterior oblique projections of baseline
and late-stage left ventriculograms to measure left ventricular
(LV) end-diastolic volume and LV ejection fraction with the
area–length method. Collateral circulation to the infarct-
related artery was evaluated according to the classifications of
Cohen and Retrop (14).
Reproducibility of data. The reproducibility of measuring
the contrast intensity was assessed by repeating MCE in five
patients. The percent absolute difference between the two
trials was 6.3 6 4.5% (mean 6 SD) for the contrast intensity.
Intraobserver and interobserver variabilities were determined
by measuring the contrast intensity in 10 randomly selected
records twice by the same observer and by two independent
observers (Y.T., H.I.) who had no knowledge of patient data or
the results of the other observer. Intraobserver and interob-
server variabilities of peak contrast intensity were 4.2 6 4.0%
and 5.1 6 4.2% (absolute difference), respectively. The repro-
ducibility of measuring the no reflow zone has been demon-
strated elsewhere (4). We assessed intraobserver and interob-
erver variabilities of the low reflow ratio using the same
patients as before. Intraobserver and interobserver variabilities
of peak contrast intensity were 4.7 6 3.3% and 5.4 6 3.2%
(absolute difference), respectively.
Statistical analysis. Results are expressed as mean value 6
SD. Multiple comparisons were made by analysis of variance
(ANOVA), and individual data were compared by the Scheffe´
F test for factor analysis. Statistical analysis of temporal
changes in certain variables was computed by two-way re-
peated measures ANOVA and the Scheffe´ F test. Differences
were considered significant at p , 0.05.
Results
Safety of intracoronary verapamil. Table 2 compares he-
modynamic and ECG variables before and after intracoronary
injection of verapamil. There was no significant change in any
variable before and after verapamil administration. No malig-
nant ventricular arrhythmias, shock or hemodynamic abnor-
malities were observed during or after intracoronary vera-
pamil.
Effect of verapamil on coronary microcirculation (Fig. 1 to
3, Table 2). Figure 1 demonstrates postinterventional MCE
images in a patient with anterior wall acute myocardial infarc-
tion before and after intracoronary injection of verapamil. A
substantial no reflow zone was observed shortly after PTCA.
After intracoronary verapamil, the no reflow zone was substan-
tially reduced.
In the verapamil group, the no or low reflow zone was
Table 2. Hemodynamic and Electrocardiographic Variables
Intracoronary Verapamil
p
ValueBefore After
SBP (mm Hg) 122 6 25 116 6 28 0.34
DBP (mm Hg) 81 6 16 71 6 17 0.09
HR (beats/min) 83 6 12 79 6 13 0.63
ECG variable
PQ int (ms) 170 6 80 174 6 30 0.41
QRS dur (ms) 80 6 10 80 6 12 0.78
QTc int (ms) 450 6 30 440 6 20 0.72
Data presented are mean value 6 SD. dur 5 duration; ECG 5 electrocar-
diographic; QTc 5 corrected QT interval (int); other abbreviations as in Table 1.
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observed within the risk area after PTCA in 14 patients. Figure
2 illustrates temporal changes in the low reflow ratio in these
14 patients. The low reflow ratio decreased significantly from
0.39 6 0.23 to 0.29 6 0.17 after verapamil administration
(percent change from before verapamil, 45 6 32%) (Fig. 2).
We then investigated whether the reduction in low reflow ratio
is attributable to the reduction in the no reflow zone or low
reflow zone, or both. Of the 14 patients, 7 were judged to have
MCE no reflow shortly after PTCA. The low reflow ratio
significantly reduced after verapamil, even in seven patients
with MCE no reflow (0.58 6 0.17 vs. 0.42 6 0.14, p , 0.005),
but the reduction in the no reflow ratio after verapamil did not
reach statistical significance (0.37 6 0.10 vs. 0.33 6 0.10, p 5
NS). Therefore, the reduction in low reflow zone (its ratio to
risk area, 0.19 6 0.14 vs. 0.07 6 0.09, p , 0.01) may contribute
to the reduction in the low reflow ratio of patients with MCE
no reflow. Thus, intracoronary verapamil can exert a salutary
effect on the preservation of the coronary microvasculature,
especially in a low reflow zone that shows patchy enhancement
or enhancement only in the epicardial layer. In contrast, MCE
revealed good contrast opacification in the risk area after
verapamil in the six patients without a no or low reflow zone.
Figure 3 shows the baseline-subtracted peak intensity in the
risk area before and after verapamil in the verapamil group.
Baseline-subtracted peak intensity in the infarct region was
lower than that in the remote normal region both before and
after verapamil (6 6 5 vs. 27 6 10, p , 0.001) but increased to
12 6 6 after verapamil (percent change, 210 6 152%, p ,
0.005 vs. before verapamil).
Coronary angiography revealed that 14 of 20 patients had
TIMI grade 3 flow before verapamil, comparable to that in the
control group (Table 1). The other six patients (30%) had
TIMI grade 2 flow despite the absence of any of residual
obstructive lesions. No patient had TIMI grade 0 or 1 patency.
After verapamil, the number of patients with TIMI grade 2
Figure 1. Myocardial contrast echocardiograms (api-
cal long-axis view) before (right) and after (left)
intracoronary administration of verapamil in a patient
with AMI. After PTCA, substantial “no reflow” phe-
nomenon showing contrast perfusion defect was ob-
served within the risk area (arrows) during injection of
contrast medium into the left main coronary artery
before verapamil administration. The size of the no
reflow area decreases after verapamil treatment.
Figure 2. Temporal changes in the low reflow ratio after intracoronary
administration of verapamil in 14 patients with no reflow or low reflow
zones shortly after PTCA. The low reflow ratio significantly decreased
after intracoronary administration of verapamil. Values are expressed
as mean 6 SD. See text for details.
Figure 3. Temporal changes in baseline-subtracted peak intensity
before and after intracoronary verapamil administration in area at risk
(ARA) and normal posterior wall (normal). After verapamil, baseline-
subtracted peak intensity increased in both areas. The values are lower
in the infarct area than in the normal area at both stages. Values are
expressed as mean 6 SD. *p , 0.001 versus area at risk. See text for
details.
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reflow decreased to 3, and 17 patients had TIMI grade 3 flow.
The number of frames required from the initiation of con-
trast injection to the opacification of the distal landmark
decreased after verapamil (50 6 15 vs. 41 6 14, p , 0.01).
Changes in these variables in individual patients are summa-
rized in Table 3.
Functional outcome. Table 4 compares LV functional out-
come between the verapamil and control groups. The wall
motion score index significantly decreased from baseline to
follow-up study in both groups. However, the magnitude of
reduction was significantly greater in the verapamil group than
in the control group. LV ejection fraction and end-diastolic
volume were compared between the two groups. There were
no differences in these variables between the two groups at
baseline. Significant improvement in LV ejection fraction was
observed in both groups, but the degree of improvement was
greater in the verapamil group than in the control group. In the
verapamil group, LV end-diastolic volume significantly de-
creased in the convalescent stage, whereas it slightly increased
in the control group. Therefore, verapamil treatment seems to
restrain LV dilation after primary PTCA.
Discussion
Our data demonstrated that intracoronary verapamil after
primary PTCA improves microvascular function, leading to
better LV functional outcome in patients with AMI than in
those treated with PTCA alone. This result implies that there
is functionally reversible microvasculature even in the no or
low reflow zone, and an increase in myocardial blood flow to
the jeopardized myocardium after intracoronary verapamil is
associated with better functional outcome than after PTCA
alone. Therefore, not only patency of the epicardial coronary
artery but also that of the coronary microvasculature could be
Table 3. Verapamil Group Patient Data
Pt No./
Gender Age (yr) Site MCE
TIMI Flow Grade
After PTCA LR Ratio PI
DLVEF
(%)
DLVEDVI
(ml/m2)Pre Post Pre Post Pre Post
1/M 57 Ant NR 2 3 0.62 0.39 11 19 20 213
2/M 70 Ant GR 3 3 0.22 0.20 17 25 12 23
3/M 64 Ant NR 2 3 0.40 0.39 1 6 32 2
4/M 36 Inf GR 3 3 0.23 0.21 8 13 8 214
5/F 60 Inf GR 3 3 0 0 13 19 12 228
6/M 56 Ant NR 3 3 0.73 0.50 1 8 212 211
7/M 61 Ant GR 3 3 0 0 17 25 22 233
8/M 51 Ant GR 3 3 0 0 16 19 230 233
9/M 64 Inf NR 2 2 0.21 0.19 2 5 215 27
10/M 65 Ant GR 3 3 0.20 0.18 3 7 221 9
11/F 54 Ant GR 3 3 0.20 0.12 2 17 19 26
12/M 52 Ant GR 3 3 0.15 0.11 5 5 224 23
13/M 57 Ant NR 2 2 0.43 0.18 6 16 16 29
14/M 64 Inf GR 3 3 0 0 20 32 5 210
15/F 79 Ant GR 3 3 0.21 0.18 18 18 11 21
16/F 59 Inf GR 3 3 0 0 13 26 12 16
17/F 79 Inf NR 2 3 0.78 0.59 9 13 19 10
18/M 75 Ant GR 3 3 0.19 0.18 23 20 11 28
19/M 61 Inf GR 3 3 0 0 10 16 10 29
20/M 64 Ant NR 2 2 0.72 0.55 11 17 220 8
Ant 5 anterior wall; Inf 5 inferior wall; F 5 female; GR 5 good reflow; LR ratio 5 low reflow ratio; LVEDVI 5 left ventricular end-diastolic volume index;
LVEF 5 left ventricular ejection fraction; M 5 male; MCE 5 myocardial contrast echocardiographic findings; NR 5 no reflow; PI 5 baseline-subtracted peak intensity;
Post 5 after intracoronary verapamil; Pre 5 before intracoronary verapamil; Pt 5 patient; D 5 late (day 225) minus acute (day 21); other abbreviations as
in Table 1.
Table 4. Left Ventricular Functional Outcome
Verapamil
Group
Control
Group
p
Value
WMSI
Acute 2.9 6 0.9 2.8 6 1.3 0.64
Late 2.2 6 1.0* 2.7 6 0.6* 0.02
D 0.7 6 0.8 0.2 6 1.3 0.02
LVEF (%)
Acute 48 6 11 47 6 9 0.68
Late 51 6 15 48 6 15 0.51
D 4 6 18 21 6 13 0.71
LVEDVI (ml/m2)
Acute 93 6 13 97 6 23 0.58
Late 90 6 22 114 6 21* 0.004
D 23 6 17 17 6 24 0.005
LVESVI (ml/m2)
Acute 48 6 13 51 6 13 0.49
Late 41 6 13 62 6 19 0.01
D 27 6 18 11 6 23 0.01
*p , 0.05 versus acute. Data presented are mean value 6 SD. Acute 5 day
21; Late 5 day 225; LVESVI 5 left ventricular end-systolic volume index;
WMSI 5 wall motion score index; other abbreviations as in Table 3.
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achieved and maintained with adjunctive pharmacologic treat-
ment to obtain optimal myocardial salvage in patients with
AMI.
Effect of verapamil on microvascular dysfunction. Several
clinical studies have demonstrated (1,3,6,10,15,16) that slug-
gish coronary flow, implying angiographic no reflow, is some-
times observed after coronary intervention despite the absence
of a flow-restricting epicardial coronary lesion in patients with
coronary heart disease. In general, this phenomenon responds
promptly to intracoronary verapamil so that microvascular
spasm may be reversed. However, to our knowledge, there has
been no systematic study of whether intracoronary verapamil
actually attenuates microvascular dysfunction in patients with
AMI. In the present study, intracoronary verapamil markedly
reduced the frequency of TIMI grade 2 flow and the number of
cineframes required until opacification of the distal landmark,
implying an increase in coronary flow. Our data indicate that
the increase in coronary blood flow was associated with a
decrease in the size of the no or low reflow zone and an
increase in baseline-subtracted peak contrast intensity, indicat-
ing attenuation of postischemic microvascular dysfunction.
Moreover, this improvement was observed particularly in the
low reflow zone, where myocardial perfusion is partially pre-
served. However, after verapamil there was no significant
reduction in the no reflow zone, where myocardial perfusion is
very low or nearly absent. Thus, intracoronary verapamil may
attenuate microvascular dysfunction, especially in the low
reflow zone after PTCA in patients with AMI, and this
attenuation may be associated with an increase in coronary
blood flow.
Microvascular dysfunction, including the no reflow or low
reflow phenomenon, is caused by several factors that increase
microvascular impedance, such as neutrophil plugging of the
capillaries, myocyte contracture, tissue edema, endothelial
blistering and microvascular spasm (17–20). Several experi-
mental and clinical reports (10,21) support the contribution of
distal microvascular spasm to the microvascular dysfunction.
Wilson et al. (22) showed reduced coronary blood flow and
transient myocardial ischemia after PTCA only in patients with
unstable angina or AMI, which are associated with coronary
thrombus. Because angina was not relieved by nitroglycerin or
thrombolytic drugs, they considered that profound spasm of
the distal microvasculature was probably caused by the release
of potent vasoconstrictors from cellular elements (platelet and
neutrophil) contained within the thrombus. In a canine exper-
iment, calcium channel antagonists were found to alleviate
impairment of endothelium-dependent vasorelaxation caused
by transient ischemia (23). This potent vasodilation of the
distal microcirculation may contribute to the favorable re-
sponse of the no reflow phenomenon to intracoronary vera-
pamil in the present study.
In the present study, the no reflow zone did not totally
disappear, and baseline-subtracted peak contrast intensity was
still lower in the infarct region than in the normal region even
after intracoronary verapamil. Thus, verapamil administration
could not totally reverse microvascular dysfunction. Other
factors that were not reversed by verapamil administration,
such as neutrophil plugging, myocyte contracture, tissue edema
and endothelial blistering, could also contribute to the patho-
genesis of the no reflow phenomenon. Babbitt et al. (9)
suggested that selective administration of adenosine after
reperfusion in dogs significantly attenuates functional and
structural abnormalities of the previously ischemic microvas-
culature. They speculated that this beneficial response is
caused by attenuation of neutrophil activities with adenosine.
Thus, the additional administration of adenosine may further
benefit microvascular salvage.
Effect of verapamil on myocardial salvage. Although the
mechanism of verapamil in the salvage of postischemic myo-
cardium is still speculative, several hypotheses have been
postulated: 1) Because verapamil works to lower heart rate and
arterial pressure, the reduced global oxygen demand may have
at least partially contributed to the reduction in infarct size
(24,25). In fact, reduction of oxygen demand has been shown
(26) to reduce infarct size. However, heart rate and blood
pressure values were comparable between the verapamil and
control groups, even before and after verapamil. 2) Verapamil
may inhibit platelet aggregation and possibly thrombus forma-
tion in the coronary microvasculature, thereby reducing the
obstruction to coronary blood flow and the degree of ischemia
(27). 3) The mechanism is related to its vasodilator effect on
the microvasculature. An increase in myocardial blood flow
could attenuate the progression of myocardial necrosis and
could thereby reduce infarct size (23,28). A previous study (8)
demonstrated that small-vessel dilation produced by dipyrida-
mole and papaverine administration also enhanced the con-
tractile function of the stunned myocardium. This effect is
possibly due to a reduction of the heterogeneity of flow that
may exist at the microvascular level. 4) Verapamil may have a
direct effect on calcium flux across the sarcolemmal membrane
or within intracellular compartments that could have resulted
in a protective action on reversibly injured myocytes.
Study limitations. The optimal dose of intracoronary vera-
pamil for attenuating microvascular dysfunction remains un-
certain. However, we chose the dose on the basis of results of
a recent study (10). The timing of verapamil administration is
another issue. We administrated verapamil after identification
of the presence or absence of the no reflow phenomenon.
Whether verapamil can be adequately delivered to the micro-
vascular bed even after the establishment of the no reflow
phenomenon is uncertain. Earlier administration of verapamil
might lead to better improvement in the coronary microvascu-
lature and myocardial function.
Semiquantitative and quantitative evaluation of cineangio-
grams was influenced by several factors, such as oxygen
consumption, hemodynamic variables (heart rate and blood
pressure), coronary artery size and local autoregulation. The
results of MCE should also be considered in the light of several
limitations of the analysis. Contrast intensity is influenced by
many factors, including the size and number of microbubbles,
factors altering ultrasound reflection, such as gain setting,
depth of penetration, incident angle, axial and lateral resolu-
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tion, gray-scale compression and the nonlinearity of echocar-
diographic amplitude signals.
Clinical implications. Success or failure of coronary inter-
vention should be ideally assessed with the recovery of myo-
cardial perfusion. However, the major end point of many
angiographic trials has been a patent infarct-related artery.
Our results clearly indicate that a patent infarct-related artery
does not necessarily guarantee patency of the coronary micro-
vasculature in patients with AMI. Administration of intracoro-
nary verapamil can partially recover microvascular integrity
and augment coronary blood flow, resulting in the recovery of
good functional outcome. An experimental study (29) has
documented a similar salutary effect of diltiazem in attenuating
ischemic myocardial injury. Therefore, recanalization of the
epicardial coronary artery should not be the only goal. Adjunc-
tive pharmacologic treatment (intracoronary verapamil) can
also protect the coronary microvasculature against ischemic
injury so that optimal myocardial salvage can be achieved in
patients with AMI.
We acknowledge the excellent technical assistance of Yuzo Sakagami, Masakazu
Ueda, Naoki Jonishi and Hideji Shimokawa.
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